Please assess the completion status of the following clinical trial:

Trial Title: Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Registration: Patients having both diffuse and follicular architectural elements will be considered eligible if the histology is predominantly follicular (≥ 50% of the cross-sectional area), and there is no evidence of transformation to a large cell histology.~* Biopsy-proven diagnosis of Grade 1 or 2 follicular non-Hodgkin's lymphoma with no evidence of transformation to large cell histology.~* Meet criteria for Low Tumor Burden:~  * No nodal or extra nodal mass ≥ 7 centimeter (cm)~ * \<3 nodal masses \>3 cm in diameter~ * No systemic symptoms or B symptoms~ * No splenomegaly \>16 cm by CT scan~ * No risk of compression of a vital organ.~ * No leukemic phase with \>5000/mm³ circulating lymphocytes.~* No cytopenias defined as:~  * Platelets \<100,000/mm³~ * Hemoglobin (Hgb) \<10 g/dL~ * Absolute Neutrophil Count (ANC) \<1500/mm³~* Must have Stage III or Stage IV disease.~* Baseline measurements/evaluations obtained within 6 weeks of registration. Patient must have at least one objective measurable disease parameter.~* Age ≥ 18 years.~* Eastern Oncology Cooperative Group Performance Status 0-1.~* Must not have received investigational agents within 30 days of registration.~* Signed Institutional Review Board (IRB)-approved informed consent.~* Willing to provide blood samples for research purposes.~* Women must not be pregnant or breastfeeding.~* Women of childbearing potential and sexually active males must use an accepted and effective method of contraception.~* No prior chemotherapy, radiotherapy or immunotherapy for lymphoma.~* No prior treatment with cytotoxic drugs or rituximab for a previous cancer or another condition (e.g. rheumatoid arthritis) or prior use of an anti-CD20 antibody.~* No prior use of any monoclonal antibody within 3 months of randomization.~* No history of severe allergic/anaphylactic reactions to humanized/murine monoclonal antibodies or known sensitivity/allergy to murine products.~* No history of prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least 2 years and did not require treatment with cytotoxic drugs or rituximab.~* No major surgery within 4 weeks prior to randomization, other than for diagnosis.~* Must be Human Immunodeficiency Virus (HIV) negative.~* Have adequate organ function without growth factor and/or transfusion support within ≤ 2 weeks prior to registration:~  * ANC ≥ 1500/mm³~ * Hgb ≥ 10 g/dL~ * Platelets ≥ 100,000/mm³~ * Serum Creatinine ≤ 2x Upper Limit Normal (ULN)~ * Total Bilirubin ≤ 2x ULN~ * AST (aspartate aminotransferase)/ALT (alanine aminotransferase) ≤ 5x ULN~ * PTT (Partial Thromboplastin Time) or aPTT (activated Partial Thromboplastin Time) \>1.5x the ULN in the absence of a lupus anticoagulant~ * INR (International Normalized Ratio) \>1.5x the ULN in the absence of therapeutic anticoagulation~* No active, uncontrolled infections (afebrile for ≥ 48 hours off antibiotics).~* Must not receive immunization with attenuated live vaccines within 28 days prior to registration or during the study period.~* Must be tested for hepatitis B surface antigen (HBsAg) and total hepatitis B core antibody (anti-HBc) within 2 weeks of registration. Patients who are chronic carriers of HBsAg and anti-HBc are excluded.~* Must be tested for hepatitis C antibody within 2 week of registration. If this test is positive, patients are excluded unless a hepatitis C virus ribonucleic acid (HCV RNA) is negative.~* No evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (i.e., severe arrhythmia, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) or pulmonary disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Rituximab (Type: ACTIVE_COMPARATOR): Rituximab 375 mg/m² IV weekly for 4 weeks.
- Arm B: GA101 (Type: EXPERIMENTAL): GA101 1,000 mg IV weekly for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues